This inventor holds 2 USPTO granted patents. Top assignee: Lupin, Inc.. Active years: 2014-2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2014-2015
Title: Innovations by Pandharinath Jadhav
Introduction
Pandharinath Jadhav is a notable inventor based in Pune, India. He has made significant contributions to the field of pharmaceuticals, particularly in the development of controlled release compositions. With a total of 2 patents to his name, Jadhav's work is recognized for its innovative approach to drug delivery systems.
Latest Patents
One of Jadhav's latest patents is focused on controlled release pharmaceutical compositions of milnacipran. This composition includes Milnacipran or its pharmaceutically acceptable salts, combined with a hydrophobic release controlling agent. The unique formulation allows for the release of 90% of the total amount of Milnacipran over a period of 8 to 20 hours under specific dissolution conditions. The process of preparing this controlled release composition involves creating a first layer that includes melting the hydrophobic agent with Milnacipran, followed by cooling and sieving to obtain granules. A second layer is then prepared, which may include additional granules of the hydrophobic agent and optionally Milnacipran.
Career Highlights
Pandharinath Jadhav is currently associated with Lupin, Inc., a prominent player in the pharmaceutical industry. His work at Lupin has allowed him to focus on innovative drug formulations that enhance therapeutic efficacy and patient compliance.
Collaborations
Jadhav has collaborated with several professionals in his field, including Ashish Tiwari and Rajesh Kulkani. These collaborations have contributed to the advancement of his research and the successful development of his patented technologies.
Conclusion
Pandharinath Jadhav's contributions to pharmaceutical innovations, particularly in controlled release formulations, highlight his expertise and commitment to improving drug delivery systems. His work continues to impact the pharmaceutical industry positively.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
